...
首页> 外文期刊>Clinical Biochemistry >Blood-based biomarkers for traumatic brain injury: Evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives
【24h】

Blood-based biomarkers for traumatic brain injury: Evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives

机译:血液性生物标志物在颅脑外伤中的作用:从临床医生和临床实验室的角度评估研究方法,可用方法和潜在用途

获取原文
获取原文并翻译 | 示例

摘要

Blood-based biomarkers for traumatic brain injury (TBI) have been investigated and proposed for decades, yet the current clinical assessment of TBI is largely based on clinical symptoms that can vary widely amongst patients, and have significant overlap with unrelated disease states. A careful review of current treatment guidelines for TBI further highlights the potential utility of a blood-based TBI biomarker panel in augmenting clinical decision making. Numerous expert reviews on blood-based TBI biomarkers have been published but a close look at the methods used and the astonishing paucity of validation and quality control data has not been undertaken from the vantage point of the clinical laboratory. Further, the field of blood-based TBI biomarker research has failed to adequately examine sex and gender differences between men and women with respect to the clinical care settings, as well as differences in physiological outcomes of TBI biomarker studies. Discussions of tried-and-true laboratory techniques in addition to a few new ones already operating in the clinical laboratory are summarized with a consideration of their utility in TBI biomarker assessment. In the context of TBI biomarkers, the central concerns discussed in this review are the readiness of the clinical laboratory, the willingness of the research environment and the inherent ability of each to radically affect patient outcomes in TBI.
机译:用于创伤性脑损伤(TBI)的基于血液的生物标志物已经被研究和提出了数十年,然而,目前对TBI的临床评估主要是基于临床症状,该临床症状在患者之间可能存在很大差异,并且与无关疾病状态有显着重叠。对当前TBI治疗指南的仔细审查进一步强调了以血液为基础的TBI生物标志物面板在增强临床决策方面的潜在用途。关于基于血液的TBI生物标志物的许多专家评论已经发表,但是从临床实验室的角度出发,尚未仔细研究所用的方法,并且尚未进行验证和质量控制数据的惊人的匮乏。此外,基于血液的TBI生物标志物研究领域未能充分检查男女在临床护理环境方面的性别差异,以及TBI生物标志物研究的生理结果差异。除了在临床实验室中已经运行的一些新技术外,还对经过实践检验的实验室技术进行了讨论,并考虑了它们在TBI生物标志物评估中的效用。在TBI生物标志物的背景下,本综述中讨论的主要关注点是临床实验室的准备情况,研究环境的意愿以及每种药物从根本上影响TBI患者预后的固有能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号